Given the persistent threat of recurrent coronavirus spillovers, the conserved upregulation of EAS1 across distinct coronavirus genera suggests it may represent a potential therapeutic target for mitigating organ injury in COVID-19. This evidence concerns the gene EPB41L4A-AS1 and COVID-19.